VYKAT XR

PreclinicalSmall molecule

SSoleno Therapeutics, Inc.

VYKAT XR is one of 35 small molecule programs targeting Prader-Willi syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

Prader-Willi SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Prader-Willi Syndrome

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

2 2

Topamax

WWim Janssens

Approved

1 3

Intuniv

PPromius Pharma, LLC

Approved

1 4

Growth Hormone

Pfizer

Approved

1 5

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

3 6

Pabal

AACADIA Pharmaceuticals Inc.

Phase 3

2 7

Nutropin AQ

Roche

Phase 3

1 8

Genotropin

Pfizer

Phase 3

1 9

Sandostatin LAR

Novartis

Phase 3

1 10

Rimonabant

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prader-Willi syndrome1 trial

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

Enrolling by invitation·SSoleno Therapeutics, Inc.··NCT07450664·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VYKAT XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VYKAT XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VYKAT XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Soleno Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSoleno Therapeutics, Inc.

VYKAT XR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prader-Willi syndrome1 trial

References

Drug Info

Quick Facts

Related News